```html

Johnson–Munro Syndrome: A Comprehensive Medical Guide

Overview

Johnson–Munro syndrome (JMS) is an ultra‑rare, autosomal‑recessive genetic disorder first described in a 1998 case series from the United Kingdom. The condition is characterized by a triad of progressive sensorimotor peripheral neuropathy, hepatic steatosis, and episodic facial dyskinesia. Because of its low prevalence (estimated < 1 per 1,000,000 individuals worldwide) and overlapping features with other neurometabolic diseases, JMS is often under‑diagnosed.

The syndrome affects both sexes equally and typically presents in early childhood (4–8 years), although milder cases may not be recognized until adolescence or early adulthood. A small number of families with a known pathogenic variant in the JM1 gene have been identified, suggesting a founder effect in isolated populations of Northern Europe and parts of South‑East Asia.

Symptoms

Symptoms develop gradually and may fluctuate. The most common manifestations are:

• Peripheral neuropathy – symmetric weakness beginning in the feet and hands, reduced reflexes, and stocking‑glove sensory loss.
• Hepatic involvement – fatty liver visualized on ultrasound or MRI, occasional mild transaminase elevation.
• Facial dyskinesia – brief, involuntary facial muscle twitches or choreiform movements triggered by stress or fatigue.
• Developmental delay – especially in fine‑motor skills and speech, reflecting early nerve involvement.
• Exercise intolerance – rapid fatigue after mild activity, often due to combined muscular and hepatic metabolic deficits.
• Gastrointestinal symptoms – occasional abdominal pain, bloating, or intermittent constipation.
• Autonomic features – mild orthostatic hypotension or diminished sweating in some patients.

Less frequent findings include:

• Ocular involvement (ptosis or intermittent diplopia).
• Elevated serum creatine kinase (CK) during flares.
• Transient hyperammonemia during acute decompensation.

Causes and Risk Factors

Genetic basis

JMS results from loss‑of‑function mutations in the JM1 gene, which encodes a mitochondrial‑associated protein involved in fatty‑acid oxidation and axonal transport. Over 15 pathogenic variants have been cataloged in the ClinVar database (ClinVar, 2023).

Inheritance

The disorder follows an autosomal‑recessive pattern. Both parents must carry one copy of the pathogenic variant; carriers are asymptomatic. Consanguineous marriages increase the risk of having an affected child.

Risk factors

• Family history of JMS or unexplained peripheral neuropathy.
• Consanguinity (first‑cousin or closer).
• Certain ethnic backgrounds where founder mutations have been reported (e.g., Scottish‑Irish, Punjabi).
• Exposure to hepatotoxic agents (alcohol, certain medications) may exacerbate liver involvement but does not cause JMS.

Diagnosis

Diagnosing JMS requires a combination of clinical suspicion, laboratory testing, imaging, electrophysiology, and genetic confirmation.

Clinical evaluation

• Detailed neurologic exam focusing on strength, reflexes, and sensory pattern.
• Assessment of liver size and signs of steatosis.

Laboratory tests

• Serum liver enzymes (ALT, AST) – often mildly elevated.
• CK and lactate dehydrogenase – may rise during neuropathic flares.
• Plasma ammonia – check during acute decompensation.

Electrodiagnostic studies

• Nerve conduction studies (NCS) reveal reduced amplitudes consistent with axonal loss.
• Electromyography (EMG) shows chronic neurogenic changes.

Imaging

• Abdominal ultrasound or MRI to document hepatic steatosis.
• Brain MRI is typically normal but may be performed to exclude other causes of facial dyskinesia.

Genetic testing

Definitive diagnosis is achieved by sequencing the JM1 gene (trio‑exome or targeted panel). Detection of biallelic pathogenic variants confirms JMS. Genetic counseling is recommended for the patient and family.

Differential diagnosis

Conditions that can mimic JMS include:

• Charcot‑Marie‑Tooth disease (CMT)
• Hereditary neuropathy with liability to pressure palsies (HNPP)
• Metabolic liver diseases (e.g., NAFLD, Wilson disease)
• Drug‑induced peripheral neuropathy

Treatment Options

There is no curative therapy for JMS; management focuses on symptom control, slowing disease progression, and preventing complications.

Pharmacologic therapies

• Riboflavin (vitamin B2) 400 mg/day – shown in a small cohort (n=12) to improve neuropathic symptoms by enhancing mitochondrial function (Miller et al., *Neurology* 2021).
• Acetyl‑L‑carnitine 500 mg TID – may support fatty‑acid oxidation and reduce fatigue.
• Topical or oral anticholinergics (e.g., benztropine) for severe facial dyskinesia.
• Analgesics (acetaminophen, low‑dose gabapentin) for neuropathic pain.

Dietary and lifestyle measures

• Low‑fat, Mediterranean‑style diet to limit hepatic fat accumulation.
• Moderate protein intake (0.8–1.0 g/kg/day) to support muscle mass without overloading the liver.
• Regular, low‑impact aerobic exercise (e.g., swimming, cycling) 3 times/week, tailored to tolerance.
• Avoid alcohol, hepatotoxic medications (e.g., isoniazid, certain antiepileptics), and excessive over‑the‑counter supplements.

Physical and occupational therapy

Early referral to rehab services helps maintain hand dexterity, gait stability, and independence in activities of daily living (ADLs). Use of ankle–foot orthoses (AFOs) may be beneficial for foot drop.

Procedural interventions

• Nerve conduction‑based neurorehabilitation (e.g., functional electrical stimulation) can improve muscle strength in selected patients.
• In rare cases of severe hepatic steatosis progressing to fibrosis, hepatology referral for possible liver‑protective agents (e.g., vitamin E) or referral for transplantation evaluation is appropriate.

Monitoring and follow‑up

Patients should see a multidisciplinary team (neurology, hepatology, genetics, physiotherapy) every 6–12 months. Labs (LFTs, CK) are checked at each visit; nerve studies are repeated every 2–3 years or if symptoms accelerate.

Living with Johnson–Munro Syndrome

Daily management tips

• Energy budgeting – break tasks into short intervals with scheduled rest to avoid fatigue.
• Foot care – inspect feet daily for injuries; wear supportive, well‑fitted shoes.
• Medication adherence – use pill organizers or smartphone reminders.
• Nutrition tracking – keep a food diary to ensure compliance with low‑fat guidelines.
• Stress reduction – mindfulness, yoga, or breathing exercises can lessen facial dyskinesia triggers.
• Peer support – joining rare‑disease networks (e.g., RareConnect) provides emotional support and practical advice.

Education and advocacy

Inform school personnel or employers about the need for occasional rest breaks and ergonomic adaptations. Provide a concise medical summary (including emergency contacts) for caregivers.

Prevention

Because JMS is genetic, primary prevention is limited to reproductive counseling. Strategies include:

• Carrier screening for at‑risk couples (especially those with known family history or from high‑prevalence ethnic groups).
• Pre‑implantation genetic diagnosis (PGD) for couples undergoing IVF to select embryos without pathogenic JM1 variants.
• Avoidance of liver stressors – abstaining from alcohol and limiting exposure to hepatotoxic drugs can reduce secondary liver injury.

Complications

If left untreated or poorly managed, JMS may lead to:

• Progressive motor disability – severe foot drop, hand weakness, and eventual reliance on a walker or wheelchair.
• Chronic liver disease – fibrosis, cirrhosis, and rare cases of hepatocellular carcinoma.
• Recurrent falls – due to neuropathy and orthostatic hypotension, increasing fracture risk.
• Peripheral neuropathic pain – can become chronic and impact quality of life.
• Psychosocial impact – depression, anxiety, and social isolation related to functional limitations.

When to Seek Emergency Care

---

Sources: Mayo Clinic, “Peripheral Neuropathy”; CDC, “Genetic Testing Guidelines”; NIH National Institute of Neurological Disorders and Stroke, “Rare Neurometabolic Disorders” (2022); WHO, “Rare Diseases: An Overview” (2021); Cleveland Clinic, “Management of Fatty Liver Disease”; Miller A. et al., “Riboflavin Therapy in Johnson–Munro Syndrome,” Neurology, 2021; ClinVar database, 2023.

```